<p>沃尔格林联合博姿（NASDAQ:WBA - 获取免费报告）于周二公布了季度财报。这家药房运营商报告本季度每股收益（EPS）为 0.63 美元，超出市场共识预期的 0.53 美元，超出幅度为 0.10 美元，Zacks 报道。该公司本季度的收入为 385.9 亿美元，超过分析师预期的 379 亿美元。沃尔格林联合博姿的股本回报率为 17.61%，净利润率为-5.87%。与去年同期相比，沃尔格林联合博姿本季度的收入增长了 4.1%。在去年同期，该公司每股收益为 1.20 美元。</p>
<h2>沃尔格林联合博姿股价上涨 0.3%</h2>
<ul>
<li>MarketBeat 周报 – 03/10 - 03/14</li>
</ul>
<p>NASDAQ:WBA 的股票周二开盘价为 10.71 美元。沃尔格林联合博姿的 12 个月最低价为 8.08 美元，最高价为 19.48 美元。该公司的流动比率为 0.64，速动比率为 0.30，债务与股本比率为 0.68。该公司的市值为 92.6 亿美元，市盈率为-1.05，市盈增长比率为 1.31，贝塔值为 0.67。该公司的 50 日移动平均线为 10.74 美元，200 日移动平均线为 10.00 美元。</p>
<h2>华尔街分析师观点</h2>
<p>WBA 已成为多份研究分析报告的主题。德意志银行将沃尔格林联合博姿的评级从 “持有” 下调至 “卖出”，并在 2 月 28 日的研究报告中将其目标价从 11.00 美元下调至 9.00 美元。加拿大皇家银行在 1 月 15 日的报告中将沃尔格林联合博姿的目标价从 9.00 美元上调至 12.00 美元，并给予该公司 “行业表现” 评级。Wolfe Research 在 2 月 24 日的报告中将沃尔格林联合博姿的评级上调至 “持有”。Evercore ISI 在 1 月 13 日的报告中将沃尔格林联合博姿的目标价从 9.00 美元上调至 12.00 美元，并给予该公司 “与大盘持平” 评级。最后，美国银行在 1 月 13 日的报告中将沃尔格林联合博姿的目标价从 7.50 美元上调至 8.50 美元，并给予该股票 “表现不佳” 评级。四位研究分析师对该股票给予了卖出评级，七位给予了持有评级，两位给予了买入评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “持有”，共识目标价为 10.59 美元。</p>
<ul>
<li>沃尔格林联合博姿：不要轻易放弃这个资产冠军</li>
</ul>
<p><strong>阅读我们关于 WBA 的最新研究报告</strong></p>
<h2>关于沃尔格林联合博姿</h2>
<p>（获取免费报告）</p>
<p>沃尔格林联合博姿公司在美国、英国、德国及国际上运营，作为一家医疗、药房和零售公司。它通过三个部门运营：美国零售药房、国际和美国医疗。美国零售药房部门从事零售药店的运营、健康与保健服务、专业药房和家庭送药服务，提供健康与保健、美容、个人护理和消费品以及一般商品。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票，胜过沃尔格林联合博姿</li>
<li>股票市场升级：它们是什么？</li>
<li>巴菲特的下一个石油投资：为什么西方石油与众不同</li>
<li>股票评级和推荐：理解分析师评级</li>
<li>谁主导了 2024 年的回购？提示：不是大型科技公司</li>
<li>投资的股票类型各异</li>
<li>阿里巴巴陷入关税交火：现在是买入时机吗？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9V0JB?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9V0JB"/></p>
<ul>
<li>Teva Pharma：为什么这家仿制药巨头现在是一个明智的投资</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1000 美元在沃尔格林联合博姿吗？</h2>
<p>在考虑沃尔格林联合博姿之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前买入……而沃尔格林联合博姿并不在名单上。</p>
<p>虽然沃尔格林联合博姿目前在分析师中获得了减持评级，但顶级分析师认为这五只股票更值得投资。</p>
<p>查看这五只股票</p>

沃尔格林联合博姿

<p>沃尔格林联合博姿（NASDAQ:WBA）报告季度每股收益为 0.63 美元，超出预期的 0.53 美元，超过 0.10 美元。公司营收为 385.9 亿美元，超过预期的 379 亿美元，同比增长 4.1%。尽管净利润率为负的 5.87%，但实现了 17.61% 的股本回报率。分析师对该股票的评级不一，平均评级为 “持有”，共识目标价为 10.59 美元</p>

<p>Walgreens Boots Alliance (NASDAQ:WBA - Get Free Report) announced its quarterly earnings data on Tuesday. The pharmacy operator reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.53 by $0.10, Zacks reports. The firm had revenue of $38.59 billion for the quarter, compared to analysts' expectations of $37.90 billion. Walgreens Boots Alliance had a positive return on equity of 17.61% and a negative net margin of 5.87%. Walgreens Boots Alliance's revenue for the quarter was up 4.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.20 earnings per share.</p>
<div class="lb-trans"><p>沃尔格林联合博姿（NASDAQ:WBA - 获取免费报告）于周二公布了季度财报。这家药房运营商报告本季度每股收益（EPS）为 0.63 美元，超出市场共识预期的 0.53 美元，超出幅度为 0.10 美元，Zacks 报道。该公司本季度的收入为 385.9 亿美元，超过分析师预期的 379 亿美元。沃尔格林联合博姿的股本回报率为 17.61%，净利润率为-5.87%。与去年同期相比，沃尔格林联合博姿本季度的收入增长了 4.1%。在去年同期，该公司每股收益为 1.20 美元。</p>
</div><h2>Walgreens Boots Alliance Trading Up 0.3 %</h2>
<div class="lb-trans"><h2>沃尔格林联合博姿股价上涨 0.3%</h2>
</div><ul>
<li>MarketBeat Week in Review – 03/10 - 03/14</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 周报 – 03/10 - 03/14</li>
</ul>
</div><p>Shares of NASDAQ:WBA opened at $10.71 on Tuesday. Walgreens Boots Alliance has a twelve month low of $8.08 and a twelve month high of $19.48. The company has a current ratio of 0.64, a quick ratio of 0.30 and a debt-to-equity ratio of 0.68. The firm has a market cap of $9.26 billion, a P/E ratio of -1.05, a P/E/G ratio of 1.31 and a beta of 0.67. The company has a 50 day moving average of $10.74 and a 200-day moving average of $10.00.</p>
<div class="lb-trans"><p>NASDAQ:WBA 的股票周二开盘价为 10.71 美元。沃尔格林联合博姿的 12 个月最低价为 8.08 美元，最高价为 19.48 美元。该公司的流动比率为 0.64，速动比率为 0.30，债务与股本比率为 0.68。该公司的市值为 92.6 亿美元，市盈率为-1.05，市盈增长比率为 1.31，贝塔值为 0.67。该公司的 50 日移动平均线为 10.74 美元，200 日移动平均线为 10.00 美元。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>WBA has been the topic of several research analyst reports. Deutsche Bank Aktiengesellschaft cut Walgreens Boots Alliance from a &#34;hold&#34; rating to a &#34;sell&#34; rating and reduced their price objective for the stock from $11.00 to $9.00 in a research note on Friday, February 28th. Royal Bank of Canada lifted their price target on shares of Walgreens Boots Alliance from $9.00 to $12.00 and gave the company a &#34;sector perform&#34; rating in a report on Wednesday, January 15th. Wolfe Research raised shares of Walgreens Boots Alliance to a &#34;hold&#34; rating in a report on Monday, February 24th. Evercore ISI upped their target price on Walgreens Boots Alliance from $9.00 to $12.00 and gave the company an &#34;in-line&#34; rating in a report on Monday, January 13th. Finally, Bank of America raised their price target on Walgreens Boots Alliance from $7.50 to $8.50 and gave the stock an &#34;underperform&#34; rating in a report on Monday, January 13th. Four research analysts have rated the stock with a sell rating, seven have given a hold rating and two have issued a buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of &#34;Hold&#34; and a consensus price target of $10.59.</p>
<div class="lb-trans"><p>WBA 已成为多份研究分析报告的主题。德意志银行将沃尔格林联合博姿的评级从 “持有” 下调至 “卖出”，并在 2 月 28 日的研究报告中将其目标价从 11.00 美元下调至 9.00 美元。加拿大皇家银行在 1 月 15 日的报告中将沃尔格林联合博姿的目标价从 9.00 美元上调至 12.00 美元，并给予该公司 “行业表现” 评级。Wolfe Research 在 2 月 24 日的报告中将沃尔格林联合博姿的评级上调至 “持有”。Evercore ISI 在 1 月 13 日的报告中将沃尔格林联合博姿的目标价从 9.00 美元上调至 12.00 美元，并给予该公司 “与大盘持平” 评级。最后，美国银行在 1 月 13 日的报告中将沃尔格林联合博姿的目标价从 7.50 美元上调至 8.50 美元，并给予该股票 “表现不佳” 评级。四位研究分析师对该股票给予了卖出评级，七位给予了持有评级，两位给予了买入评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “持有”，共识目标价为 10.59 美元。</p>
</div><ul>
<li>Walgreens Boots Alliance: Don’t Write Off This Asset Champ Yet</li>
</ul>
<div class="lb-trans"><ul>
<li>沃尔格林联合博姿：不要轻易放弃这个资产冠军</li>
</ul>
</div><p><strong>Read Our Latest Research Report on WBA</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 WBA 的最新研究报告</strong></p>
</div><h2>About Walgreens Boots Alliance</h2>
<div class="lb-trans"><h2>关于沃尔格林联合博姿</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Walgreens Boots Alliance, Inc operates as a healthcare, pharmacy, and retail company in the United States, the United Kingdom, Germany, and internationally. It operates through three segments: U.S. Retail Pharmacy, International, and U.S. Healthcare. The U.S. Retail Pharmacy segment engages in operation of the retail drugstores, health and wellness services, specialty, and home delivery pharmacy services, which offers health and wellness, beauty, personal care and consumables, and general merchandise.</p>
<div class="lb-trans"><p>沃尔格林联合博姿公司在美国、英国、德国及国际上运营，作为一家医疗、药房和零售公司。它通过三个部门运营：美国零售药房、国际和美国医疗。美国零售药房部门从事零售药店的运营、健康与保健服务、专业药房和家庭送药服务，提供健康与保健、美容、个人护理和消费品以及一般商品。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Walgreens Boots Alliance</li>
<li>Stock Market Upgrades: What Are They?</li>
<li>Buffett’s Next Oil Bet: Why Occidental Is Different</li>
<li>Stock Ratings and Recommendations: Understanding Analyst Ratings</li>
<li>Who Led Buybacks to End 2024? Hint: It Wasn’t Big Tech</li>
<li>There Are Different Types of Stock To Invest In</li>
<li>Alibaba Caught in Tariff Crossfire: Is It Time to Buy?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过沃尔格林联合博姿</li>
<li>股票市场升级：它们是什么？</li>
<li>巴菲特的下一个石油投资：为什么西方石油与众不同</li>
<li>股票评级和推荐：理解分析师评级</li>
<li>谁主导了 2024 年的回购？提示：不是大型科技公司</li>
<li>投资的股票类型各异</li>
<li>阿里巴巴陷入关税交火：现在是买入时机吗？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9V0JB" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=WBA"/></p>
<ul>
<li>Teva Pharma: Why This Generic Drug Giant Is a Smart Buy Now</li>
</ul>
<div class="lb-trans"><ul>
<li>Teva Pharma：为什么这家仿制药巨头现在是一个明智的投资</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Walgreens Boots Alliance Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在沃尔格林联合博姿吗？</h2>
</div><p>Before you consider Walgreens Boots Alliance, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑沃尔格林联合博姿之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Walgreens Boots Alliance wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前买入……而沃尔格林联合博姿并不在名单上。</p>
</div><p>While Walgreens Boots Alliance currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然沃尔格林联合博姿目前在分析师中获得了减持评级，但顶级分析师认为这五只股票更值得投资。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

沃尔格林联合博姿（NASDAQ:WBA）公布季度收益结果，每股收益超出预期 0.10 美元